To better understand the role of ERO1α in pancreatic cancer progression, we next deleted the corresponding gene using CRISPR/Cas genome editing technology and assessed the impact on tumor cell function both in vitro and in vivo. This evidence concerns the gene ERO1A and familial pancreatic carcinoma.